Although numerous studies using the transient middle cerebral artery occlusion (tMCAO) model have reported positive results (137), a pivotal study using a thromboembolic stroke model, which more closely mimics the clinical reality, found that blocking the NLRP3 pathway, either through genetic knockout or pharmacological inhibition with MCC950, had no effect on the extent of stroke-induced damage (138). This evidence concerns the gene NLRP3 and stroke disorder.